Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Trellus Health PLC ( (GB:TRLS) ) has issued an update.
Trellus Health PLC has entered into an unsecured loan agreement with its substantial shareholder, Icahn School of Medicine at Mount Sinai, for $600,000 to support its commercial strategy and extend its cash runway to January 2026. The loan, which is non-interest bearing for the first six months, will help the company focus on securing additional commercial contracts with pharmaceutical companies and CROs, with recent contracts signed with two leading global CROs to implement trials by year-end.
More about Trellus Health PLC
Trellus Health PLC is a healthcare company that provides value-based innovative solutions and services to help individuals with chronic conditions manage their health. The company offers Trellus Elevate®, a digital platform that combines data analytics with personalized resilience programs to manage complex chronic conditions, with an initial focus on gastrointestinal conditions like Inflammatory Bowel Disease (IBD). Trellus Health also provides Trellus TrialSet™, a solution for pharmaceutical partners to support clinical trials and patient engagement.
Average Trading Volume: 887,288
Technical Sentiment Signal: Sell
Current Market Cap: £847.9K
See more data about TRLS stock on TipRanks’ Stock Analysis page.